前立腺がん治療の世界市場2016-2026...市場調査レポートについてご紹介

【英文タイトル】The Prostate Cancer Market 2016-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1. The Prostate Cancer Therapeutics Market Overview
1.2. Prostate Cancer Therapeutics Market Segmentation
1.3. Why You Should Read This Report
1.4. How This Report Delivers
1.5. Key Questions Answered by This Analytical Report
1.6. Who is This Report For?
1.7. Methodology
1.8. Frequently Asked Questions (FAQ)
1.9. Associated Reports
1.10. About Visiongain

2. Introduction to Prostate Cancer
2.1. What Is Cancer?
2.2. Phenotypic Characteristics of Cancer Cells
2.2.1. Uncontrolled Growth
2.2.2. Loss of Functioning Apoptotic Pathways
2.2.3. Lack of Differentiation
2.2.4. Increased Angiogenesis
2.2.5. Potential for Metastasis
2.2.6. Genetic Instability
2.3. What Causes Cancer?
2.3.1. Worldwide Prevalence of Cancer: A Global Picture
2.4. What is Prostate Cancer?
2.4.1. Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.4.2. Risk Factors for Prostate Cancer
2.5. How is Prostate Cancer Diagnosed?
2.5.1. PSA Testing
2.5.2. Digital Rectal Examination Testing
2.5.3. Prostate Cancer Screening: Does the Cost Justify the Means?
2.5.4. Alternative Tests Could Change Diagnostics
2.6. Treating Prostate Cancer
2.6.1. Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.6.1.1. Brachytherapy
2.6.1.2. Radical Prostatectomy
2.6.1.3. External Beam Radiation Therapy
2.6.1.4. Cryotherapy
2.6.1.5. High-Intensity Focused Ultrasound (HIFU)
2.6.2. Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
2.6.3. Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.6.4. Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
2.6.5. First Line Chemotherapy: Docetaxel is a Standard Treatment
2.6.6. Post Docetaxel Therapy: Five FDA Approved Drugs
2.6.7. Second Line Chemotherapy: Jevtana Approved in 2010

3. The Prostate Cancer Therapeutics Market 2016-2026
3.1. The Global Prostate Cancer Therapeutics Market, 2014
3.2. The Global Prostate Cancer Therapeutics Market Forecast, 2016-2026
3.3. The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2016-2026

4. The Prostate Cancer Drugs Market 2016-2026
4.1. The Prostate Cancer Drugs Market: Greater Choice of Drugs Increasing Competition in the mCRPC Setting
4.2. The Prostate Cancer Drugs Market, 2015
4.3. Leading Prostate Cancer Drugs: Market Forecast, 2015-2025
4.4. Market Share of Leading Prostate Cancer Drugs, 2016-2026
4.5. First Generation Chemotherapies
4.5.1. Taxotere (Sanofi)s
4.5.1.1. Taxotere Sales, 2014
4.5.1.2. Taxotere Sales Forecast, 2016-2026
4.6. Second Generation Chemotherapies
4.6.1. Jevtana (Sanofi)
4.6.1.1. Jevtana Sales, 2014 & 2015
4.6.1.2. Jevtana Sales Forecast, 2016-2026
4.7. First Generation Hormones
4.7.1. Casodex (AstraZeneca)
4.7.1.1. Casodex Sales, 2014 & 2015
4.7.1.2. Casodex Sales Forecast, 2016-2026
4.7.2. Leuplin (Takeda) / Lupron (AbbVie)
4.7.2.1. Leuplin & Lupron Sales, 2014 & 2015
4.7.2.2. Leuplin & Lupron Sales Forecast, 2016-2026
4.7.3. Zoladex (AstraZeneca)
4.7.3.1. Zoladex Sales, 2014 & 2015
4.7.3.2. 2 Zoladex Sales Forecast, 2015-2025
4.8. Second Generation Hormones
4.8.1. Zytiga (Johnson & Johnson)
4.8.1.1. Zytiga Sales, 2014 & 2015
4.8.1.2. Zytiga Sales Forecast, 2016-2026
4.8.2. Xtandi (Medivation/ Astellas Pharma)
4.8.2.1. Xtandi Sales, 2014 & 2015
4.8.2.2. Xtandi Sales Forecast, 2016-2026
4.9. Radiopharmaceuticals
4.9.1. Xofigo (Bayer)
4.9.1.1. Xofigo Sales, 2014 & 2015
4.9.1.2. Xofigo Sales Forecast, 2016-2026
4.10. Other Drugs
4.11. Prostate Cancer Drugs Pipeline, 2016
4.11.1. Phase III Development
4.11.1.1. DCVax-Prostate (NorthWest Biotherapeutics)
4.11.1.2. Tookad Soluble (Steba Biotech)
4.11.1.3. ProstAtak (Advantagene)
4.11.1.4. ARN-509 (Johnson & Johnson)
4.11.1.5. Custirsen (Oncogenex)
4.11.1.6. Prostvac (Bavarian Nordic)
4.11.1.7. Galeterone (Tokai Pharmaceuticals)
4.11.2. Phase II development
4.11.2.1. GDC-0068 (Roche)
4.11.2.2. PSMA ADC (Progenics Pharmaceuticals)
4.11.2.3. Apatorsen (OGX-427 – OncoGenex Pharmaceuticals)
4.11.3. Phase I
4.11.3.1. RG7450 (Roche)
4.11.3.2. BAY2010112 (Bayer Pharmaceuticals)
4.11.3.3. BPX-201 (Bellicum Pharmaceuticals)

5. The Prostate Cancer Devices Market, 2016-2026
5.1. The Prostate Cancer Devices Market 2014
5.2. The Prostate Cancer Devices Market Forecast, 2016-2026
5.3. The Market Shares of Leading Prostate Cancer Devices Submarkets, 2016-2026
5.4. The Radical Prostatectomy Market 2016-2026
5.4.1. Intuitive Surgical’s da Vinci Surgical System
5.5. The External Beam Radiation Therapy Market, 2016-2026
5.6. The Brachytherapy Market 2016-2026
5.7. The Cryotherapy Market 2016-2026
5.8. The HIFU Market, 2016-2026

6. The Leading Companies in the Prostate Cancer Therapies Market, 2016
6.1. The Leading Companies in the Prostate Cancer Drugs Market, 2016
6.2. Johnson & Johnson (J&J)
6.2.1. Sales and Performance Analysis, 2015
6.2.2. Pharmaceutical Segment Sales Analysis, 2015
6.2.3. Oncology Drugs Sales and Performance Analysis, 2015
6.2.4. Pharmaceutical Segment R&D Performance Analysis, 2015
6.2.5. Acquisition of Aragon Pharmaceuticals
6.3. AstraZeneca
6.3.1. Sales and Performance Analysis, 2015
6.3.2. Pharmaceutical Segment Sales & R&D Analysis by Segment, 2015
6.3.3. Oncology Drugs Sales and Performance Analysis, 2015
6.4. Sanofi
6.4.1. Sales and Performance Analysis, 2015
6.4.2. Sales and Performance Analysis by Segment, 2015
6.4.3. Oncology Sales and Performance Analysis, 2015
6.4.4. R&D Performance Analysis, 2015
6.4.5. Oncology Pipeline Portfolio
6.5. AbbVie
6.5.1. Sales and Performance Analysis, 2015
6.5.2. R&D Performance Analysis, 2015
6.5.3. Humira: From “First-In-Class” to “Best-In-Class”, 2015
6.5.4. Oncology Portfolio Pipeline Products, 2015
6.6. Leading Companies in the Prostate Cancer Devices Market 2016-2026
6.7. Varian Medical Systems
6.7.1. Sales and Performance Analysis, 2015
6.7.2. Oncology Segment Sales Analysis, 2015
6.7.3. Sales Analysis by Region, 2015
6.7.4. R&D Performance Analysis, 2015
6.7.5. Key Oncology Products, 2015
6.7.6. Varian and Siemens Partnership: Shaping the Future of Cancer Care
6.8. Elekta
6.8.1. Sales and Performance Analysis, 2015
6.8.2. Sales and Performance Analysis by Region, 2015
6.8.3. Elekta and Philips Establish Research Consortium
6.8.4. Product Launch and Development, 2015
6.9. Theragenics Corporation (acquired by Juniper Acquisition Corporation)
6.9.1. Theragenics Sales Performance Analysis, 2014
6.9.2. Theragenics Sales Performance by Operation, 2012
6.9.3. Sales and Performance Analysis by Business Unit, 2012
6.9.4. Mergers and Acquisitions
6.9.4.1. Juniper’s acquisition of Theragenics
6.9.4.2. Acquisition of US & Canadian Seed Business of Eckert & Ziegler BEBIG
6.9.4.3. Acquisition of Needle Tech Products
6.9.4.4. Acquisition of Galt Medical

7. The Leading National Markets, 2016-2026
7.1. Regional Breakdown of the Prostate Cancer Therapeutics Market, 2014
7.2. The Prostate Cancer Therapeutics Market: Regional Forecast, 2016-2026
7.3. Market Shares Forecasts of Leading National Prostate Cancer Therapeutics Markets, 2016-2026
7.4. The US Prostate Cancer Therapeutics Market 2016-2026
7.5. The European Prostate Cancer Therapeutics Market, 2014
7.6. The European Prostate Cancer Therapeutics Market, 2015-2025
7.6.1. The German Prostate Cancer Therapeutics Market, 2016-2026
7.6.2. The French Prostate Cancer Therapeutics Market, 2016-2026
7.6.3. The UK Prostate Cancer Therapeutics Market, 2015-2025
7.6.4. The Spanish Prostate Cancer Therapeutics Market, 2016-2026
7.6.5. The Italian Prostate Cancer Therapeutics Market, 2016-2026
7.7. The Japanese Prostate Cancer Therapeutics Market, 2016-2026
7.8. The Chinese Prostate Cancer Therapeutics Market, 2016-2026
7.9. The Brazilian Prostate Cancer Therapeutics Market, 2016-2026
7.10. The Russian Prostate Cancer Therapeutics Market, 2016-2026
7.11. The Indian Prostate Cancer Therapeutics Market, 2016-2026
7.12. The South Korean Prostate Cancer Therapeutics Market, 2016-2026
7.13. The Rest of the World Prostate Cancer Therapeutics Market, 2016-2026

8. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2016-2026
8.1. SWOT Analysis, 2016-2026
8.2. Strengths
8.2.1. Rapidly Ageing Male Populations Worldwide
8.2.2. A Number of Promising Pipeline Drug Candidates
8.2.3. Successful Partnerships Between Big and Small Pharmaceutical Companies Leading to New Products
8.3. Weaknesses
8.3.1. High Treatment Costs
8.3.2. High Levels of Phase III Attrition
8.4. Opportunities
8.4.1. Rising Incidence of Cancer
8.4.2. Development of Emerging Markets
8.5. Threats
8.5.1. Concerns about Efficacy and Toxicity of Drugs
8.5.2. Increase in Generic Competition
8.5.3. Healthcare Budget Restraints
8.6. Porter’s Five Force Analysis
8.6.1. Rivalry Among Competitors [High]
8.6.2. Threat of New Entrants [High]
8.6.3. Power of Suppliers [Low]
8.6.4. Power of Buyers [High]
8.6.5. Threat of Substitutes [Low]

9. Conclusions
9.1. The Prostate Cancer Therapeutics Market, 2016-2026
9.2. The US Will Remain the Largest National Market from 2016 to 2026
9.3. Concluding Remarks

10. Glossary


【レポート販売概要】

■ タイトル:前立腺がん治療の世界市場2016-2026
■ 英文:The Prostate Cancer Market 2016-2026
■ 発行日:2016年4月
■ 調査会社:visiongain
■ 商品コード:VGAIN60627
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。